Generative Vision-Language Radiology Model Gains FDA Breakthrough Device Designation
The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device Designation to the Cognita Chest X-Ray for multiple indications.
The Cognita Chest X-Ray is a generative vision-language AI model that assists with the interpretation of chest X-rays. Developer Mosaic Clinical Technologies noted that Cognita Chest X-Ray is the first radiology generative AI model to receive the FDA’s Breakthrough Device Designation.
The model analyzes imaging studies and creates a comprehensive preliminary finding for physician review that is integrated with radiology workflows and can be finalized by licensed radiologists.
The device has undergone preliminary internal clinical validation, which has demonstrated the potential for improved diagnostic accuracy, according to the developer. Radiologists using Cognita Chest X-Ray experienced enhanced detection of 16% to up to 65%, and an average interpretation efficiency boost of 18%.
Cognita Chest X-Ray is also incorporated into MosaicOS, a fully cloud-native and AI-native operating system.
As a part of the Breakthrough designation, Cognita will be granted closer collaboration with the FDA to assist in bringing the technology to market to address a growing workforce shortage and growing demand for diagnostic imaging.
ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.
Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results of a recent study published in JAAD International.
“This type of cancer, which is a result of mutations of the most common cell type in the top layer of the skin, is strongly linked to accumulated [ultraviolet] radiation over time. It develops in sun-exposed areas, often on skin already showing signs of sun damage, with rough scaly patches, uneven pigmentation, and decreased elasticity,” stated lead researcher Sam Polesie, MD, PhD, Associate Professor of Dermatology and Venereology at the University of Gothenburg and Practicing Dermatologist at Sahlgrenska University Hospital, both in Gothenburg, Sweden.